Exploring skeletal muscle tolerance and whole-body metabolic effects of FDA-approved drugs in a volumetric muscle loss model.

Physiol Rep · 2023 · PMC10277213 · PMID 37332022

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a slight trendno p-value reported

Nintedanib's mechanism of action is downstream of TGFβ signaling, and while there was a slight trend to lower TGFβ1 with both nintedanib and formoterol, this was not significant (Table 2 ).

also in 1,309 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.